@chuminhua432 Avatar @chuminhua432 Minhua Chu

Minhua Chu posts on X about china, ipo, core, $azn the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [-----] #

Followers Line Chart

CreatorRank: [---------] #

CreatorRank Line Chart

Social Influence

Social category influence countries 37.39% stocks 34.78% finance 31.3% travel destinations 10.43% vc firms 8.7% currencies 8.7% cryptocurrencies 4.35% technology brands 2.61% exchanges 1.74% financial services 0.87%

Social topic influence china 35.65%, ipo #199, core 7.83%, $azn #117, company 6.09%, has been 5.22%, shanghai 5.22%, $lly #108, approved #623, in the 4.35%

Top accounts mentioned or mentioned by @notgenentech @yaireinhorn

Top assets mentioned AstraZeneca PLC (AZN) Eli Lilly and Company (LLY) Sanofi (SNY) One Cash (ONC) GSK plc (GSK) NovaBridge Biosciences (NBP) Merck & Co., Inc. (MRK) Johnson & Johnson (JNJ) Novartis AG (NVS) Gilead Sciences, Inc. (GILD) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Adlai Nortye Ltd (ANL) Structure Therapeutics Inc. (GPCR) Axion (AXN) Instil Bio, Inc. (TIL) Vertex Protocol (VRTX)

Top Social Posts

Top posts by engagements in the last [--] hours

"Genhouse Bio inks global collaboration with $GILD for GH31 GH31 is a biomarkerdriven synthetic lethality therapy targeting MAT2A it has already received IND clearance in China and US. 🔹 $80M upfront 🔹 Up to $1.45B milestones 🔹 Tiered doubledigit royalties Gilead will receive exclusive global rights to develop and commercialize GH31. https://mp.weixin.qq.com/s/YqppaFXcZP2mofN8ZPy7LQ https://mp.weixin.qq.com/s/YqppaFXcZP2mofN8ZPy7LQ"
X Link 2026-02-13T14:15Z [----] followers, 13.5K engagements

"Marketing approvals - supplementary approvals firmonertinib third-generation EGFR-TKI by Allist Pharma Adult patients with locally advanced or metastatic NSCLC who have experienced disease http://x.com/i/article/2021223361482014720 http://x.com/i/article/2021223361482014720"
X Link 2026-02-10T14:48Z [----] followers, [---] engagements

"Regend Therapeutics has completed a RMB [---] million Series C financing round. Founded in [----] Regend focuses on the regenerative medicine for human organs using progenitor cells. Regend's founders are from Tsinghua University. This year Regend will start Phase [--] clinical trials of REGEND001 for the treatment of COPD and IPF in China. Pulmovinci developed based on an optimized process of REGEND001 has been granted Orphan Drug Designation by the FDA for IPF. In early [----] REGEND001 was listed in pilot programs in the Hainan Boao Lecheng International Medical Pilot Zone for three indications:"
X Link 2026-02-11T08:55Z [----] followers, [---] engagements

"Betta Pharmaceuticals announced that it has received marketing approval for its pertuzumab biosimilar for the treatment of early-stage and metastatic breast cancer in China"
X Link 2026-02-11T10:19Z [----] followers, [---] engagements

"$LLY announced that two formulations of mirikizumab (Omvoh) have been approved by the NMPA for the treatment of adults with moderate to severe active Crohn's disease (CD) and adults with moderate to severe active ulcerative colitis (UC)"
X Link 2026-02-11T10:59Z [----] followers, [---] engagements

"$MDGL has entered into a global licensing deal with Suzhou Ribo Life Science for six preclinical small interfering RNA programs to treat a type of liver disease. upfront payment of $60 million with total payments across the programs potentially reaching up to $4.4 billion if certain milestones are met. Suzhou Ribo will also receive royalties on future net sales. https://www.reuters.com/business/healthcare-pharmaceuticals/madrigal-suzhou-ribo-license-deal-liverdisease-programs-2026-02-11/"
X Link 2026-02-11T11:07Z [----] followers, [---] engagements

"Exclusive: Sanofi invests in China startup developing molecular glue for sickle cell disease https://endpoints.news/sanofi-invests-in-china-startup-developing-molecular-glue-for-sickle-cell/ https://endpoints.news/sanofi-invests-in-china-startup-developing-molecular-glue-for-sickle-cell/"
X Link 2026-02-11T14:37Z [----] followers, [---] engagements

"UniXell Biotechnology announced that it has completed a Series A+ financing round of over RMB [--] million led by Panlin Capital Qunchun Venture Capital and Waigaoqiao Private Equity Fund. UniXell is a biotech focused on developing innovative stem cellbased therapeutics supported by its high-throughput lineage-tracing technology and iPSC platforms. Lead candidate UX-DA001 is an autologous cell therapy for Parkinsons disease already received IND approvals in both China and the US. It has also received FDA Fast Track designation. UX-DA001 is currently in a Phase [--] clinical trial in China."
X Link 2026-02-12T09:11Z [----] followers, [---] engagements

"Ascletis selects ASC36 its first oral amylin receptor peptide agonist for clinical development Ascletis plans to submit an IND to the FDA in Q2 for ASC36 oral tablets for obesity treatment. https://www.ascletis.com/news_detail/200/id/1346.html https://www.ascletis.com/news_detail/200/id/1346.html"
X Link 2026-02-12T15:03Z [----] followers, [---] engagements

"In Jan. [----] China NMPA approved [--] NMEs for marketing (2 approved at the end of [----] but announced in Jan.) [--] cancer drugs: $ONC sonrotoclax (conditional approval) BCL2 inhibitor for blood cancer; http://x.com/i/article/2021965637837570048 http://x.com/i/article/2021965637837570048"
X Link 2026-02-12T16:32Z [----] followers, [---] engagements

"Shenzhen Immunofoco Biotechnology submitted HKSE IPO application: Founded in [----] Immunofoco is cell therapy company. Core Product: 🔹IMC002 anti-CLDN18.2 CAR T cell therapy candidate for treatment of solid tumors in a pivotal Phase III clinical trial. Other clinical stage candidate: 🔹IMC001: anti-EpCAM CAR-T cell therapy for treatment of solid tumors Phase I/IIa [--] in vivo CAR-T cell therapy candidates 🔹hematological malignancies (IMV [---] and IMV102) 🔹autoimmune diseases (IMV101) 🔹solid tumors (IMV103) https://www1.hkexnews.hk/app/sehk/2026/108200/documents/sehk26021300028.pdf"
X Link 2026-02-13T15:39Z [----] followers, [---] engagements

"Salubris Pharma submitted HKSE IPO application: Salubris already listed in Shenzhen stock market and focuses on Cardiovascular-Kidney-Metabolic (CKM) field. [--] marketed innovative drugs Under development: 🔹SAL0140 (a highly selective ASI) 🔹SAL0120 (a selective ETAR antagonist) both for uncontrolled or resistant hypertension and CKD. https://www1.hkexnews.hk/app/sehk/2026/108199/documents/sehk26021201241.pdf https://www1.hkexnews.hk/app/sehk/2026/108199/documents/sehk26021201241.pdf"
X Link 2026-02-13T16:32Z [----] followers, [---] engagements

"FindCure Biosciences recently completed a Series B round exceeding RMB [---] million accelerating clinical development and platform expansion. FindCure is a clinicalstage biotech company pioneering nextgeneration cancer therapies across immunooncology and radiopharmaceuticals. 🔹 FC084 a Phase [--] program in combination with PD1 therapy. 🔹 RDC: Powered by the proprietary InnoRDC platform [--] IIT-stage RDC candidates https://twitter.com/i/web/status/2022633647476715888 https://twitter.com/i/web/status/2022633647476715888"
X Link 2026-02-14T11:26Z [----] followers, [---] engagements

"#Innovent Biologics' clinical trial application for #IBI3026 has been accepted by the #NMPA. IBI3026 is a fusion protein of a PD-1 antibody and IL-12. Some key facts about IBI 3026: https://www.linkedin.com/feed/update/urn:li:activity:7360336440011993088/ https://www.linkedin.com/feed/update/urn:li:activity:7360336440011993088/"
X Link 2025-08-22T14:32Z [----] followers, [----] engagements

"$ZLAB Zai Lab has registered its first Ph3 clinical trial of ZL-1310 (zocilurtatug pelitecan) This randomized open-label clinical trial (n=665) aims to evaluate the efficacy and safety of ZL-1310 (at two dose levels) compared with investigator's choice (Tarlatamab Topotecan Lurbinectedin or Amrubicin) in patients with relapsed SCLC. The primary endpoints are cORR and OS. ZL-1310 is an ADC targeting DLL3 discovered by MediLink Therapeutics using its TAMLIN technology platform. In April [----] Zai Lab and MediLink Therapeutics entered an agreement acquiring global rights for ZL-1310. In ASCO2025"
X Link 2025-10-21T12:45Z [----] followers, [----] engagements

"NovaBridge Biosciences (I-Mab) application for HKSE IPO has been accepted. Its core product givastomig is a CLDN18.2/4-1BB bsAb. It had established a pipeline consisting of three clinical stage programs as of the Latest Practicable Date including two oncology programs uliledlimab and ragistomig as well as an ophthalmology program VIS-101. https://x.com/chuminhua432/status/1979230110109831631 https://twitter.com/i/web/status/1984305942314557487 https://www1.hkexnews.hk/app/sehk/2025/107826/documents/sehk25103100038.pdf https://x.com/chuminhua432/status/1979230110109831631"
X Link 2025-10-31T17:06Z [----] followers, [---] engagements

"Innovent Biologics announced that mazdutide (IBI362) a dual GLP-1/glucagon receptor agonist met the primary endpoint and all key secondary endpoints in the Phase [--] GLORY-2 study in Chinese adults with moderate-to-severe obesity (BMI [--] kg/m or [--] kg/m with weight-related comorbidities). At Week [--] the mazdutide [--] mg group achieved a mean weight reduction of 18.55% compared to 3.02% in the placebo group. 44.0% of participants in the mazdutide [--] mg group achieved a weight reduction of 20% or more versus 2.6% in the placebo group (P0.0001 for all comparisons). The key secondary endpoints"
X Link 2025-11-20T07:44Z [----] followers, [----] engagements

"$ZLAB announced that China's NMPA approved the New Drug Application (NDA) for COBENFY (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. The NMPAs approval of COBENFY is supported by the results from a Phase [--] pharmacokinetics (PK) study conducted inChina the Phase [--] China study (ZL-2701-001) and data from three global EMERGENT clinical studies. Zai Labhas an exclusive license fromKaruna Therapeutics Inc. a company acquired by Bristol Myers Squibb to develop manufacture and commercialize COBENFY in Greater China"
X Link 2025-12-24T15:14Z [----] followers, [----] engagements

"According to NMPA's CDE website Innovent Biologics has submitted a clinical trial application for a new drug IBI3028. According to Innovent Biologics' previous interim report IBI3028 is a bispecific-antibody dual-toxin ADC with the target undisclosed. The antibody structure may employ a 1+1 asymmetric structure and the toxin may adopt a 4+4 form. bispecific-antibody dual-toxin ADCs already got clinical trial approval in China: - DXC [---] HER2 bispecific epitope ADC by Hangzhou DAC Biotech. - JSKN021 EGFR/HER3 ADC by Alphamab Oncology - TJ102 CDH6/FR ADC by Phrontline Biopharma (also has 5"
X Link 2025-12-29T04:50Z [----] followers, [----] engagements

"Innovent Biologics announced that ipilimumab N01 injection (IBI310 not biosimiliar) a CTLA-4 monoclonal antibody has been approved for marketing by NMPA for use in combination with sintilima as neoadjuvant therapy in patients with surgically resectable stage IIB-III MSI-H or dMMR colorectal cancer. Previously the results of the randomized controlled open-label NeoShot-1b study of ipilimumab N01 in combination with sintilimab as neoadjuvant therapy for MSI-H/dMMR colorectal cancer were published in Cancer Cell. https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00396-4"
X Link 2025-12-29T09:44Z [----] followers, [----] engagements

"Adlai Nortye Ltd. ($ANL) announced that it has entered into an exclusive l#icensing agreement with Aosaikang Pharmaceutical Co. Ltd. (ASK Pharma) for the development and commercialization of its investigational pan-RAS (ON) inhibitor AN9025 in mainland China Hong Kong and Macao. AN9025 is an oral small molecule pan-RAS(ON) inhibitor Under the terms of the agreement ASK Pharma will obtain exclusive rights to develop manufacture and commercialize AN9025 in the licensed territory while Adlai Nortye retains global rights outside Greater China. The company is eligible to receive up to RMB 1.6"
X Link 2025-12-29T15:30Z [----] followers, [----] engagements

"$GPCR Structure Therapeutics through its subsidiary Gasherbrum Bio entered into a non-exclusive patent licensing agreement with $RHHBY Roche and Genentech receiving a $100 million upfront payment. The agreement finalized on Dec. [--] [----] allows Roche and Genentech to use certain patents covering a class of oral GLP-1 receptor agonists that is different from $GPCR's aleniglipron. Genentech will pay Gasherbrum a one-time non-refundable payment of $100 million within thirty (30) days after execution of the GNE Agreement. Genentech agreed to pay Gasherbrum royalties at a low single digit rate on"
X Link 2026-01-06T07:46Z [----] followers, [----] engagements

"ImmuneOnco announced that Axion Bio Inc. a wholly-owned subsidiary of $TIL has decided to discontinue clinical development of IMM2510/AXN-2510. Axion and ImmuneOnco have entered into an agreement terminating their license and collaboration agreement for IMM2510/AXN-2510 and IMM27M/AXN-27M. The termination will not affect the upfront and milestone payments of $35 million that ImmuneOnco has received from Axion. IMM2510/AXN-2510 is a novel PD-L1xVEGF bispecific antibody incorporating a VEGF receptor trap capable of binding multiple VEGF receptor ligands beyond VEGF-A as well as"
X Link 2026-01-07T09:37Z [----] followers, [----] engagements

"$ZLAB announced that China NMPA has approved the sNDA for Augtyro (repotrectinib) for the treatment of adult patients with solid tumors harboring NTRK gene fusions. These patients are those with locally advanced metastatic solid tumors or those for whom surgical resection would likely result in serious complications and who have failed prior treatment or have no satisfactory alternative therapy. This is the second indication approved for repotrectinib in China. In May [----] the China NMPA approved repotrectinib for the treatment of adult patients with locally advanced or metastatic"
X Link 2026-01-07T13:07Z [----] followers, [---] engagements

"NMPA has conditionally approved the marketing of sorotoclax (BGB-11417) an innovative drug developed by $ONC through a priority review and approval process. This drug is approved for - adult patients with CLL/SLL who have previously received at least one systemic therapy including BTK inhibitors - adult patients with relapsed or refractory MCL who have previously received at least two prior systemic therapies (including BTK inhibitors). Sortoclax is a potent and highly selective BCL-2 inhibitor https://twitter.com/i/web/status/2008891134731509838"
X Link 2026-01-07T13:19Z [----] followers, [---] engagements

"$HCM Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Sovleplenib is a novel spleen tyrosine kinase (Syk) inhibitor HUTCHMED is also developing the therapy for immune thrombocytopenia with an NDA resubmission to the NMPA for second-line use in the condition planned in the first half. https://twitter.com/i/web/status/2009134884619735133"
X Link 2026-01-08T05:27Z [----] followers, [---] engagements

"Chengdu Zenitar Biomedical announced the completion of a nearly RMB [---] million Series C financing round. This round was co-led by Temasek's wholly-owned subsidiary Temasek Capital and Qiming Venture Partners"
X Link 2026-01-12T04:19Z [----] followers, [---] engagements

"$GMAB discontinued the development of [--] drugs from Profound https://www.oncologypipeline.com/apexonco/one-genmab-rybrevant-challenge-rendered-moot https://www.oncologypipeline.com/apexonco/one-genmab-rybrevant-challenge-rendered-moot"
X Link 2026-01-22T14:52Z [----] followers, [----] engagements

"$AZN plans to invest $15 billion in China through [----] to pioneer the next-generation of innovative medicines expanding the capabilities in breakthrough treatments like cell therapy and radioconjugates https://news.cision.com/se/astrazeneca/r/astrazeneca-plans-to-invest--15-billion-in-china-through-2030-to-pioneer-the-next-generation-of-innoc4299606 https://news.cision.com/se/astrazeneca/r/astrazeneca-plans-to-invest--15-billion-in-china-through-2030-to-pioneer-the-next-generation-of-innoc4299606"
X Link 2026-01-30T04:28Z [----] followers, [----] engagements

"$AZN enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals [--] next-generation therapies for obesity and type [--] diabetes. Once-monthly injectable weight management portfolio - [--] clinical-ready asset SYH2082 a long-acting GLP1R/GIPR agonist progressing into Phase I - [--] preclinical programmes with differing mechanisms Financial terms - upfront payment of $1.2 billion milestones of up to $3.5 billion across all programmes - up to US$13.8 billion in potential sales milestone payments plus up to double-digit royalties based on the annual net sales of the"
X Link 2026-01-30T09:31Z [----] followers, [---] engagements

"HSG (formerly known as Sequoia Capital China) announced the completion of its global acquisition of the core product Avelox (moxifloxacin) and the establishment of Hangzhou Shanze Bio an innovative biopharmaceutical company focusing on anti-infectives and respiratory diseases and its parent company Ascenda Pte. Ltd. to operate this business. According to the agreement Shanze and its parent company Ascenda acquired specific assets of Avelox globally including drug registration certificates intellectual property rights and business contracts in relevant countries and regions laying a solid"
X Link 2026-02-03T08:25Z [----] followers, [---] engagements

"Innovent Biologics' IBI3013 has been approved for entering clinical trials in China as treatments for vitiligo and alopecia areata. IBI3013 is novel monoclonal antibody with an extended half-life targeting IL-15. The preclinical studies of IBI3013 will be presented at EADV [----]. https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eadv/abstracts_congress_2025/53927.pdf https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eadv/abstracts_congress_2025/53927.pdf"
X Link 2026-02-04T12:02Z [----] followers, [----] engagements

"Hangzhou-based iMBioRay announced that it has recently completed a Series B #financing of nearly RMB [---] million led by Deep Intelligent Pharma (DIP) an AI-powered drug R&D service company. Since its establishment in [----] iMBioRay has focused on the NK cell therapy field. The company has built four original technology platforms: - CAR-raNKa unique CAR delivery platform; - tiNKan immune-trained NK cell platform; - ANKERan antibody-guided NK connector platform; - mRNA vaccine technology platform. [--] product submitted marketing application [--] in Phase [--] iMBioRay just completed Series A+ financing"
X Link 2026-02-05T09:52Z [----] followers, [---] engagements

"Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan Serplulimab a novel anti-PD-1 monoclonal antibody developed by Henlius In China it has been approved for sqNSCLC ES-SCLC nsNSCLC ESCC. In the EU it has been approved for ES-SCLC. Eisai will obtain exclusive rights to commercialize serplulimab in Japan. upfront payment of USD [--] million regulatory milestone payments of up to USD [-----] million sales milestone payments of up to USD [-----] million double-digit royalties based on sales of the product."
X Link 2026-02-05T15:33Z [----] followers, [---] engagements

"Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013 in China and Asia-Pacific (excluding Japan). MT1013 a polypeptide targeting the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor is primarily developed with Secondary Hyperparathyroidism (SHPT) upfront payment of RMB [---] million and potential regulatory and commercial milestone payments of up to RMB [----] million. https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-exclusive-license-agreement-with-micot-to-commercialize-mt1013-302679600.html"
X Link 2026-02-05T15:40Z [----] followers, [---] engagements

"$EVGN and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128 a Microbiome-Based Therapeutic for Renal and Lung Cancer LS-LBP-002is a live biopharmaceutical consortium composed of four human gut bacterial strains with defined functional capabilities that enhance responses to immunotherapy and stimulate anti-tumor immune activity. LS-LBP-002is currently completing a Phase [--] clinical study in renal cell carcinoma and non-small cell lung cancer and has demonstrated encouraging early clinical promise. Financial terms did not disclosed."
X Link 2026-02-05T15:59Z [----] followers, [---] engagements

"$MRK announced that its PD-1 inhibitor pembrolizumab (Keytruda) has been approved by NMPA for 1L treatment of adult patients with dMMR primary advanced or recurrent endometrial cancer in combination with carboplatin and paclitaxel followed by maintenance therapy with pembrolizumab monotherapy. This new indication approval is based on data from the Phase III clinical trial KEYNOTE-868 (NRG-GY018). This approval marks the 20th indication for pembrolizumab to be approved in China. https://twitter.com/i/web/status/2019701947809648897 https://twitter.com/i/web/status/2019701947809648897"
X Link 2026-02-06T09:17Z [----] followers, [----] engagements

"Bio-Thera and Avalon Pharma Execute Exclusive Commercialization Agreement for BAT3306 a Proposed Keytruda Biosimilar for Saudi Arabia and MENA Bio-Thera will maintain responsibility for development manufacturing and supply of BAT3306. Avalon Pharmawill be responsible for seeking regulatory approvals as well as commercialization in the licensed territories in Saudi Arabia and MENA. https://www.bio-thera.com/col_62/1375.html https://www.bio-thera.com/col_62/1375.html https://www.bio-thera.com/col_62/1375.html https://www.bio-thera.com/col_62/1375.html"
X Link 2026-02-07T12:00Z [----] followers, [---] engagements

"Innovent Announces Strategic Collaboration with $LLY to Develop New Medicines Globally in Oncology and Immunology This agreement marks the seventh collaboration between the two companies. Innovent will lead the development of programs from concept through clinical proof-of-concept (Phase [--] clinical trial completion) in China. The agreement grants Lilly an exclusive license to develop and commercialize the programs worldwide outside Greater China while Innovent retains rights in Greater China. Innovent will receive a $350 million upfront payment and is eligible to receive development"
X Link 2026-02-08T14:16Z [----] followers, [----] engagements

"Cascade Pharmaceuticals announced the successful completion of a new financing round of nearly RMB [---] million. This round was led by Zhongping Capital. Lead candidate: CS0159"
X Link 2026-02-10T07:57Z [----] followers, [---] engagements

"TenNor Therapeutics submitted HKSE IPO application. [--] candidates including [--] Core Products - rifasutenizol (TNP-2198) used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of H. pylori infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China; - rifaquizinone (TNP-2092 injection) a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections i.e. ABSSSI and PJI LVADI and CRBSI in China and the U.S."
X Link 2026-02-10T09:53Z [----] followers, [---] engagements

"WuXi Biologics and $VRTX Sign License and Research Service Agreement for T-cell Engager an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases. Financial terms didnot disclosed. https://www.prnewswire.com/news-releases/wuxi-biologics-and-vertex-sign-license-and-research-service-agreement-for-t-cell-engager-302677027.html https://www.prnewswire.com/news-releases/wuxi-biologics-and-vertex-sign-license-and-research-service-agreement-for-t-cell-engager-302677027.html"
X Link 2026-02-04T08:27Z [----] followers, [----] engagements

"$JNJ reported [----] Q3 earnings 6.8% sales increase to $24 billion BCMA CAR-T therapy Carvyktideveloped in partnership with Legend Biotechsaw significant sales growth. Carvykti achieved total sales of $524 million in Q3 [----] marking an 83.5% yoy increase. Carvykti's sales have already surpassed $1 billion this year totaling $1.332 billion exceeded its full-year total from [----] which was $963 million. https://twitter.com/i/web/status/1978396388808593549 https://twitter.com/i/web/status/1978396388808593549"
X Link 2025-10-15T09:43Z [----] followers, [----] engagements

"$NBP (formerly called I-Mab) announced positive updated results from the Phase 1b combination study of givastomig a Claudin [----] (CLDN18.2) x 4-1BB bispecific antibody in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative first line (1L) metastatic gastric cancer. NovaBridge said that givastomig has unique molecular design to balance anti-tumor efficacy and safety https://www.novabridge.com/news-releases/news-release-details/novabridge-presents-positive-givastomig-dose-expansion-data"
X Link 2026-01-07T13:48Z [----] followers, [----] engagements

"$JNJ announced that its innovative anti-CD38 mab daratumumab subcutaneous injection has received supplementary approval from China's NMPA for in combination with bortezomib lenalidomide and dexamethasone for the treatment of newly diagnosed adult patients with multiple myeloma who are eligible for autologous stem cell transplantation. This approval is based on the results of the Phase [--] PERSEUS study. https://twitter.com/i/web/status/2020847830076957122 https://twitter.com/i/web/status/2020847830076957122"
X Link 2026-02-09T13:10Z [----] followers, [---] engagements

"$AZN released its [----] financial report Revenue in China reached a record high of $6.654 billion an increase of 4% yoy accounting for 11% of total revenue and 43.48% of emerging markets. https://files.quartr.com/reports/7b87f-2026-02-10.pdfref=TWFya2V0QmVhdCBNZWRpYSBMTEM= https://files.quartr.com/reports/7b87f-2026-02-10.pdfref=TWFya2V0QmVhdCBNZWRpYSBMTEM="
X Link 2026-02-10T08:48Z [----] followers, [---] engagements

"Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase [--] Obesity Trial of Oral Ribupatide once-daily oral ribupatide (also known as HRS9531 tablet and KAI-9531-T) a GLP-1/GIP receptor dual agonist peptide Week [--] participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg) 12.1% (25 mg) and 12.1% (50 mg) from baseline with no observed plateau in weight loss compared to 2.3% with placebo."
X Link 2026-02-11T05:07Z [----] followers, [---] engagements

"RemeGen advances PD1/VEGF BsAb RC148 into Phase [--] RemeGen has registered its first Phase [--] clinical trial RC148C30) of RC148 (RC148C301) on China CDE in 1L squamous NSCLC going headtohead with tislelizumab. The primary endpoint is PFS. 2L NSCLC Phase [--] study has also been cleared in both China and the US following Chinas Breakthrough Therapy Designation in [----]. In Jan. RemeGen licensed global rights (exChina) for RC148 to $ABBV in a deal worth up to $5.6B including $650M upfront. https://x.com/chuminhua432/status/2010724516788617505s=20"
X Link 2026-02-12T13:30Z [----] followers, [---] engagements

"Vaccine manufacturer Kangtai Biological Products (BioKangtai) announced that it has decided to terminate the proposed JV with $AZN. In March [----] BioKangtai and AstraZeneca planned to jointly establish a JV in the Beijing with a registered capital of approximately RMB [---] million ($50 million). BioKangtai and AstraZeneca would each hold 50% of the equity and the total investment in the JV was estimated at approximately $400 million (approximately RMB [----] billion). The JV was originally planned to develop localize manufacture and commercialize globally innovative vaccines (expected to include"
X Link 2026-02-08T14:37Z [----] followers, [---] engagements

"QuantX Biosciences Closes Oversubscribed $85M Series B Financing Round co-led by LAV and Sanofi Ventures QuantX Biosciences is a privately held pharmaceutical company advancing oral small-molecule medicines through a computationally driven drug discovery platform. https://www.globenewswire.com/news-release/2026/02/09/3234526/0/en/QuantX-Biosciences-Closes-Oversubscribed-85M-Series-B-Financing.html https://www.globenewswire.com/news-release/2026/02/09/3234526/0/en/QuantX-Biosciences-Closes-Oversubscribed-85M-Series-B-Financing.html"
X Link 2026-02-10T06:47Z [----] followers, [---] engagements

"$LLY China announced that Mounjaro (tirzepatide) has been approved by NMPA for use as monotherapy in adults with type [--] diabetes (T2DM). The updated label now covers both monotherapy and combination therapy with other glucoselowering agents. The approval is primarily based on the SURPASSCNMONO study led by Professor Mu Yiming Director of the Department of Endocrinology at the General Hospital of the Peoples Liberation Army. The study evaluated the efficacy and safety of tirzepatide monotherapy versus placebo in Chinese adults with type [--] diabetes."
X Link 2026-02-12T09:31Z [----] followers, [---] engagements

"$LLY China announced that its noncovalent (reversible) BTK inhibitor Jaypirca (pirtobrutinib) has been approved by NMPA for a new indication. The therapy is now authorized for the treatment of adult patients with CLL or SLL who have received at least one prior systemic therapy that included a BTK inhibitor. The approval is based on results from the BRUIN CLL321 Phase III study an international multicenter randomized controlled trial. https://twitter.com/i/web/status/2021882715956719687 https://twitter.com/i/web/status/2021882715956719687"
X Link 2026-02-12T09:42Z [----] followers, [---] engagements

"ProteLight Pharmaceuticals submitted HKSE IPO application: ProteLight is a innovative antimicrobial peptide (AMP) therapeutics company established in April [----]. Core product: 🔹PL-5 (Peceleganan) Ganan-class drug that has filed a NDA [--] key products: 🔹PL-3301 thermosensitive peptide gel for the treatment of oropharyngeal candidiasis. 🔹PL-18 AMP drug for the treatment of vulvovaginal candidiasis (VVC) and other gynecological infections including bacterial vaginitis fungal vaginitis and mixed vaginitis. Preclinical assets 🔹PL-MD-333 oral FGF19/FGF21 inducer and lipid metabolism"
X Link 2026-02-13T15:21Z [----] followers, [---] engagements

"VivaVision Biotech submitted HKSE IPO application: Founded in [----] VivaVision is an ophthalmology-focused biotech company. [--] Core Products 🔹VVN461(HD) : the high-dosage formulation of VVN461 eye drop novel selective dual-target inhibitor of JAK1 and TYK2 with sub-nanomolar potency. Phase [--] clinical trial in non-infectious anterior uveitis (NIAU) patients in China. 🔹VVN001 a second-generation antagonist of lymphocyte function-associated antigen-1 (LFA-1) is an innovative eye drop for the treatment of dry eye disease (DED). Phase [--] clinical trial in China."
X Link 2026-02-13T15:48Z [----] followers, [---] engagements

"Beijing-based Mabworks' Otuoztuzumab (MIL62) a recombinant humanized antiCD20 monoclonal antibody to treat adult patients with AQP4positive neuromyelitis optica spectrum disorder (NMOSD). Otuoztuzumab is a anti-CD20 antibody featuring a fucoseknockout design to enhance ADCC. In a Phase [--] trial Otuoztuzumab reduced relapse risk by 97.5% vs placebo (ARR: [-----] vs 1.024; HR=0.025; P0.001) with median time to first relapse not reached in the treatment arm. https://twitter.com/i/web/status/2022653897979130200 https://twitter.com/i/web/status/2022653897979130200"
X Link 2026-02-14T12:47Z [----] followers, [---] engagements

"Takeda $TAK has entered into a license and collaboration agreement with Innovent Biologics for two late-stage oncology medicines IBI363 and IBI343 worldwide outside of Greater China. IBI363 PD-1/IL-2-bias bispecific antibody fusion protein is being evaluated in NSCLC and CRC IBI343 a Claudin [----] ADC is being evaluated in gastric and pancreatic cancers. Takeda will also receive an exclusive option to license global rights outside of Greater China for IBI3001 (EGFRB7H3 ADC) an early-stage investigational medicine. $1.2 billion upfront $100 million equity investment"
X Link 2025-10-22T02:31Z [----] followers, [----] engagements

"WuXi AppTec released its 2025Q3 report reporting revenue of RMB [------] billion in Q3 a yoy increase of 15.26%. And WuXi AppTec entered the agreement to sell its two subsidiaries - WuXi Clinical (Clinical CRO) and WuXi MedKey (SMO) to Hillhouse. The base equity transfer price is RMB [---] billion and the final price will be determined based on the target company's financial performance on the loan disbursement date and its performance from [----] to [----]. Payment will be made in four installments with agreed-upon installment terms and a performance betting clause. Q1-Q3 revenue of clinical CRO and"
X Link 2025-10-26T14:11Z [----] followers, [----] engagements

"Innovent Biologics said its dual GCG/GLP-1 receptor agonist mazdutide met the main goal of yet another head-to-head Phase III trial this time outshining Novo Nordisks GLP-1 drug Ozempic (semaglutide) on HbA1c and weight reduction in Chinese patients with comorbid obesity and type [--] diabetes. Mazdutide was approved for the respective conditions in China inJune andSeptember this year. The proportion of participants achieving HbA1c 7.0% and a 10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group Innovent entered into an exclusive license"
X Link 2025-10-27T10:09Z [----] followers, [----] engagements

"Shanghai Longwood Biopharmaceuticals announced the completion of a Series B+ #financing worth hundreds of millions of RMB led by Qiming Venture Partners. Longwood was founded in [----] by Dr. Wang Zhe. Dr. Zhe Wang a professor at Nankai University and an expert in medicinal chemistry. He completed his postdoctoral research at Harvard University under the tutelage of Nobel Laureate in Chemistry Elias J. Corey. Longwood focuses on the development of innovative drugs in the fields of immunotherapy antiviral therapy autoimmune diseases and tumor immunotherapy. Its core products: LW231 bi-functional"
X Link 2025-10-29T15:59Z [----] followers, [---] engagements

"Nanjing-based TransThera Sciences announced to enter into a royalty bearing patent assignment and research collaboration agreement with Neurocrine Biosciences $NBIX to develop NLRP3 inhibitors one of the Companys preclinical assets for multiple diseases. ex-Greater China develop manufacture and commercialize rights total potential value of up to US$881.5 million https://staticpacific.blob.core.windows.net/press-releases-attachments./3936472/HKEX-EPS_20251103_11898360_0.PDF https://twitter.com/i/web/status/1985607410455875590"
X Link 2025-11-04T07:17Z [----] followers, [----] engagements

"Ivacta bio an in vivo cell therapy developer announced the completion of an angel round financing exceeding [---] million RMB led by Qiming Venture Partners. Ivacta was was spun off from the in vivo CAR-T platform of GRIT Bio on June [--] [----]. Ivacta's in vivo CAR-T therapy developed based on a targeted LNP delivery system focuses on delivering revolutionary treatment options for hematological malignancies and autoimmune diseases. https://twitter.com/i/web/status/1986048072338829580 https://twitter.com/i/web/status/1986048072338829580"
X Link 2025-11-05T12:28Z [----] followers, [---] engagements

"3SBio updated Ph2 clinical data for its PD-1/VEGF BsAb SSGJ-707 + chemo in 1L NSCLC at #SITC2025 LBA abstract. SSGJ-707 [--] mg/kg the confirmed objective response rate (ORR) was 58.6% in nonsquamous 75.0% in squamous cohort A and 37.5% (paclitaxel; majority pending confirmation) and 69.2% (nab-paclitaxel) in squamous cohort B; with tislelizumab confirmed ORR was 38.7% in nonsquamous and 47.6% in squamous patients. Responses were observed irrespective of PD-L1 expression https://jitc.bmj.com/content/13/Suppl_3/A1568utm_source=researchgate.net&medium=article"
X Link 2025-11-07T15:09Z [----] followers, [---] engagements

"Nantong-based DeliNova Therapeutics a biotech pioneer focused on in vivo CAR-T therapies announced the completion of a [--] million RMB seed and angel #financing. Investors include Shanghai Jiao Tong University Hanyuan VC Legend Capital CAS Star Vision Investment and Hongfeng Investment. DeliNova's in vivo CAR-T technology is from Professor Cai Yujia's lab at Shanghai Jiao Tong University. Professor Cai's lab is focuses on the research in vivo CAR-T and other gene therapy technologies based on lentiviral vectors since [----]. https://twitter.com/i/web/status/1988255450333434207"
X Link 2025-11-11T14:40Z [----] followers, [---] engagements

"Hangzhou-based Vybio announced the completion of a Series B #financing exceeding [---] million RMB. This round was exclusively led by Qiming Venture Partners. Founded in [----] Vybio focuses on therapies for oncology and chronic diseases with several products already entering Phase I and Phase II clinical trials. Candidates in clinical stages include the highly selective aldosterone synthase inhibitor VB19055 and small molecule targeted drugs TFX05 TFX06 and VB15. https://twitter.com/i/web/status/1989321147088036328 https://twitter.com/i/web/status/1989321147088036328"
X Link 2025-11-14T13:14Z [----] followers, [----] engagements

"Luye Pharma Receives FDA Clearance of IND Application for Its Next-generation 5-HT2AR Inverse Agonist/5-HT2CR Antagonist LY03017 LY03017 is intended to treat Alzheimer's disease psychosis (ADP) Parkinson's disease psychosis (PDP) and the negative symptoms of schizophrenia (NSS). FDA has exempted the single ascending dose (SAD) trial in the Phase I clinical trial of LY03017 and the drug can directly proceed to the multiple ascending dose (MAD) trial and subsequent clinical trials. https://twitter.com/i/web/status/1992866050137010472 https://www.luye.cn/lvye_en/view.phpid=2358"
X Link 2025-11-24T08:01Z [----] followers, [----] engagements

"Innovent Biologics announces that the supplementary application for the [--] mg dosage of mazdutide a glucagon/GLP-1 dual receptor agonist for the long-term weight management in adults with moderate to severe obesity has been accepted for review by CDE of China's NMPA. This application is based on the encouraging results from the Phase [--] registration clinical study GLORY-2 (NCT06164873) of mazdutide [--] mg in Chinese adults with moderate to severe obesity."
X Link 2025-11-26T07:19Z [----] followers, [---] engagements

"Ascentage Pharma $AAPG announced the publication of clinical and translational data from a Phase Ib study (NCT03594422) on olverembatinib (HQP1351) in patients with gastrointestinal stromal tumors (GIST). The study reported in olverembatinib is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations CML in accelerated phase (CML-AP) with T315I mutations and CML-CP that is resistant or intolerant to first and second-generation TKIs. https://pubmed.ncbi.nlm.nih.gov/41184234/"
X Link 2025-11-26T07:26Z [----] followers, [---] engagements

"$ONC announced that FDA has accepted and granted Priority Review to a NDA for sonrotoclax a next-generation BCL2 inhibitor for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) following treatment with a Brutons tyrosine kinase (BTK) inhibitor. https://ir.beonemedicines.com/news/us-fda-grants-priority-review-to-sonrotoclax-for-the-treatment-of-relapsed-or-refractory-mantle/786f1dad-0c9f-492e-9fce-f9ceadd24989"
X Link 2025-11-27T15:36Z [----] followers, [----] engagements

"Innovent Biologics announces that China's NMPA has approved PECONDLE(picankibart injection) a recombinant anti-IL-23p19 antibody for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic This approval was based on a pivotal registrational Phase [--] clinical trial CLEAR-1 (NCT05645627) over 80% of subjects achieving a 90% improvement in PASI [--] at Week [--]. https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetailkey=565 https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetailkey=565"
X Link 2025-11-28T15:57Z [----] followers, [----] engagements

"ESMO Asia 2025: Hansoh Pharmaceutical will deliver an oral presentation featuring the first clinical data for its B7H3-targeted ADC HS-20093 (GSK5764227) in a NSCLC subgroup This ESMO Asia presentation reports results from the NSCLC cohort of ARTEMIS-001 treated with [---] or [----] mg/kg HS-20093 every [--] weeks (Q3W). As of the data cutoff (January [--] 2025) among [---] NSCLC patients treated at [---] mg/kg (n=93) or [----] mg/kg (n=74): - 59.9% had adenocarcinoma 39.5% had squamous cell carcinoma - Median age: [----] years - 44.9% current or former smokers - 16.2% with baseline brain metastases - Median"
X Link 2025-12-03T14:15Z [----] followers, [----] engagements

"NHSA unveiled an updated version of its national medical insurance drug list and the inaugural edition of the commercial insurance innovative drug list. New lists will be formally implemented nationwide starting January [--] [----]. The updated national medical insurance drug list has added [---] drugs among which [--] are innovative pharmaceuticals. The commercial insurance innovative drug list included [--] drugs for the treatment of tumors rare diseases and Alzheimer's among others. The [--] drugs are: [--]. Velaglucerase beta CANbridge [--]. Sapropterin Shandong New Time Pharma [--]. Teduglutide $TAK 4."
X Link 2025-12-07T15:16Z [----] followers, [----] engagements

"yes Ascletis said when ASC30 was titrated weekly its vomiting rate was about half that of $LLY's oral GLP-1 orforglipron. The findings suggest "a potential best-in-class profile of ASC30 for both weight loss and GI tolerability" said Jinzi Jason Wu founder CEO and chairman of Ascletis. https://twitter.com/i/web/status/1998321106546032886 https://twitter.com/i/web/status/1998321106546032886"
X Link 2025-12-09T09:17Z [----] followers, [---] engagements

"D3 Bio a global clinical-stage biotech focused on the discovery and development of innovative oncology therapeutics announced the completion of a $108 million Series B #financing round. The funding round was backed by IDG Capital and SongQing Capital. Existing investors WuXi AppTec's Corporate Venture Fund Temasek HSG MPCi and Medicxi also contributed to the round. Lead asset elisrasib (D3S-001) is KRAS G12C inhibitor. https://www.prnewswire.com/news-releases/d3-bio-secures-108-million-in-series-b-financing-to-advance-global-clinical-programs-302636690.html"
X Link 2025-12-10T11:55Z [----] followers, [----] engagements

"$ZEAL and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases co-discover and co-develop innovative therapies for multiple targets in metabolic diseases. - OTR Therapeutics lead and conduct research and preclinical development. - Zealand Pharma assume responsibility for clinical development regulatory submissions and commercialization worldwide. initial upfront $20 million may increase to $30 million under certain pre-agreed conditions total $ [---] billion OTR just emerged from stealth and announced the"
X Link 2025-12-11T08:56Z [----] followers, [---] engagements

"Allin Biotherapeutics a clinical-stage biotech developing next-generation ADCs and multispecific antibody drugs for oncology and immunology announced the completion of a nearly $50 million Series A+ #financing round. The round was led by existing investor Legend Capital and new investor Long-Z. [--] core candidates: - ALK201 an ADC targeting FGFR2b Phase [--] study for advanced solid tumors. - ALK202 EGFR/cMET bispecific ADC preclinical stage. In addition to ADCs the company is actively developing its proprietary Masked TCE platform. https://twitter.com/i/web/status/2000941728493432991"
X Link 2025-12-16T14:50Z [----] followers, [---] engagements

"Hansoh Pharmaceutical entered into an exclusive license collaboration and distribution agreement with Glenmark $GLENMARK Aumolertinib a third-generation EGFR-TKI for the treatment of NSCLC. licensed territories: the Middle East and Africa Southeast & South Asia Australia New Zealand Russia/CIS and a few selected Caribbean countries. No financial term disclosed https://www.hkexnews.hk/listedco/listconews/sehk/2025/1216/2025121600891.pdf https://twitter.com/i/web/status/2000942505089728778 https://www.hkexnews.hk/listedco/listconews/sehk/2025/1216/2025121600891.pdf"
X Link 2025-12-16T14:54Z [----] followers, [---] engagements

"Shenzhen-based Ocgene Biopharma a biotech focusing on the development of ophthalmic drugs has completed a $30 million Series B #financing round. This round was jointly led by a well-known industrial investor and Qiming Venture Partners. The funds raised will be fully used to support the Phase [--] clinical trials of its core productOCUL101in both China and the United States. OCUL101 an anti-VEGF and C5 bispecific antibody independently developed by Ocgene is currently undergoing Phase [--] studies for neovascular age-related macular degeneration (nAMD) diabetic macular edema (DME) and geographic"
X Link 2025-12-16T15:11Z [----] followers, [---] engagements

"ESMO ASIA Hansoh Pharmaceutical announced that the phase I study results of risvutatug rezetecan (HS-20093/GSK5764227 a B7-H3-targeted ADC) in patients with locally-advanced or metastatic NSCLC were presented in a mini oral session at ESMO Asia [----] In December [----] Hansoh granted $GSK an exclusive worldwide license (excluding the Chinese Mainland Hong Kong Macau and Taiwan) to develop manufacture and commercialize risvutatug rezetecan which is currently undergoing Phase I and Phase [--] clinical trials overseas by GSK. https://www.hspharm.com/news/news-detail-513398.htm"
X Link 2025-12-18T09:29Z [----] followers, [---] engagements

"Ipsen $IPSEY announced an exclusive #licensing agreement for global rights outside of Greater China for Simcere Zaimings SIM0613 an ADC targeting the LRRC15 protein. total paymemt: $1.06B https://www.ipsen.com/press-release/ipsen-expands-early-development-pipeline-with-simcere-zaimings-innovative-antibody-drug-conjugate-3208932/ https://www.ipsen.com/press-release/ipsen-expands-early-development-pipeline-with-simcere-zaimings-innovative-antibody-drug-conjugate-3208932/"
X Link 2025-12-22T10:01Z [----] followers, [----] engagements

"$GSK China announced that NMPA has approved Nucala (mepolizumab) for maintenance treatment of adult patients with uncontrolled COPD characterized by elevated serum eosinophil counts. This approval is based on positive data from the Phase [--] clinical trials MATINEE and METREX. Mepolizumab is a monoclonal antibody that targets IL-5. It is already approved in China for maintenance treatment of severe eosinophilic asthma (SEA) in adults and adolescents aged [--] years and older as well as for the treatment of uncontrolled chronic sinusitis with nasal polyps in adults and eosinophilic granulomatous"
X Link 2025-12-23T13:06Z [----] followers, [---] engagements

"$AZN AstraZeneca announced that its Wainua (eplontersen) co-developed with $IONS Ionis has been officially approved in China for the treatment of adult patients with hereditary transthyretin amyloid polyneuropathy (ATTRv-PN). Eplontersen is a gene silencing agent for the treatment of ATTRv-PN and is an antisense oligonucleotide (ASO) therapy. The approval in China is based on positive results from the NEUROTTRansform Phase [--] clinical trial. ATTR has been included in the second batch of National Rare Disease Catalogue. https://twitter.com/i/web/status/2005513974230524395"
X Link 2025-12-29T05:39Z [----] followers, [----] engagements

"Chengdu-based Moucellion Therapeutics has completed a Series Pre-A1 #financing worth tens of millions of RMB. This round of financing was jointly invested by IDG Capital and Shenzhen Future New Intelligent Investment. The funds raised will be used to support the pipeline development of iPSC-derived RPE cells for the treatment of AMD. Founded in March [----] Moucellion is a biotech specializing in the development of iPSC-based cell therapy and AAV-mediated gene therapy to treatophthalmic diseases. Its key pipelines include autologous iPSC-RPE cells and ABCA4 gene therapy via a dual AAV system"
X Link 2025-12-30T09:13Z [----] followers, [---] engagements

"Akeso announced that its PD-1 monoclonal antibody pempulimab has been officially approved by China's NMPA for a new indication in combination with anlotinib as first line treatment of advanced HCC. This approval marks the fifth indication for pempulimab in China. Pempulimab had been approved for: 1L squamous NSCLC relapsed or metastatic classical Hodgkin lymphoma and first-line and later-line treatment of nasopharyngeal carcinoma all of which are included in the National Reimbursement Drug List. Pempulimab has already been approved by FDA for NPC."
X Link 2025-12-31T12:37Z [----] followers, [----] engagements

"$SNY announced that Redemplo (plozasiran) injection has received marketing approval from China NMPA for use in adult patients with familial chylomicronemia syndrome (FCS) on the basis of dietary control to lower triglyceride levels. On August [--] [----] Sanofi announced an asset purchase agreement with Visirna Therapeutics a subsidiary of Arrowhead Pharmaceuticals to acquire the rights to develop and commercialize Redemplo in Greater China. https://twitter.com/i/web/status/2008885559582953962 https://twitter.com/i/web/status/2008885559582953962"
X Link 2026-01-07T12:56Z [----] followers, [---] engagements

"On January 9th Recordati (Beijing) Pharmaceutical Co. Ltd. announced on its official WeChat account that according to a formal resolution of its sole shareholder the company completed its liquidation team filing on December [--] [----] and entered into liquidation proceedings. Based on this all of the company's business activities will be gradually and orderly terminated in the near future. In the future the company will be unable to provide any form of product service or business support. Recordati Beijing was originally a branch established in Beijing in [----] by the Italian pharmaceutical group"
X Link 2026-01-11T03:43Z [----] followers, [---] engagements

"Oricell Therapeutics Announces $70M Initial Closing of Series C Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies Leadprogram Ori-C101 autologous GPC3-targeted CAR-T therapy for advanced HCC. - IIT and a Phase I IND studycompleted. - Clinical data presented in ASCO - enter the registrationalpivotal trial Platform - OriAb: antibody discovery and engineering library - OriArmoring: enhancement of T-cell persistence and other crucial functions byTAsTherapeutic Areas - OnGo (Fast) CMC: rapid scalable and effective manufacturing"
X Link 2026-01-12T03:49Z [----] followers, [----] engagements

"On Jan. [--] WuXi Biologics and WuXi XDC announced a takeover offer for BioDLink. Citi will make a voluntary conditional cash offer on behalf of the offeror for all issued shares and to cancel all outstanding share options. The acquisition price is HK$4.00 per share in cash. As of the date of this announcement BioDLink has a total of [---------] issued shares with a total share capital of approximately HK$3.091 billion. According to the announcement the final consideration for WuXi XDC to acquire 60% shares of BioDLink is expected to be HK$1.855 billion."
X Link 2026-01-15T15:59Z [----] followers, [---] engagements

"AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca $AZN C-CAR031 is an autologous GPC3-targeting CAR-T therapy designed using AstraZenecas dominant negative transforming growth factor-beta receptor II armoring platform Now in Phase [--] in China for HCC and other solid tumors AstraZeneca has agreed to acquire AbelZetas - 50% share of the China development and commercialization rights to C-CAR031 - the sole right to develop manufacture and commercialize C-CAR031 globally up to $630 million including an upfront payment and development regulatory"
X Link 2026-01-19T03:42Z [----] followers, [----] engagements

"$GSK enters agreement to acquire $RAPT The acquisition includes ozureprubart a long-acting anti-IgE monoclonal antibody currently in phase IIb clinical development for prophylactic protection against food allergens. $RAPT obtianed the ex-Mainland China right of ozureprubart (RPT904 RPT904) from Jeyou Pharmaceutical the subsidary of Jemincare in [----]. https://x.com/chuminhua432/status/1871794948166865071s=20 https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-rapt-therapeutics/"
X Link 2026-01-20T09:09Z [----] followers, [---] engagements

"According to ApexOnco $PFE recently canned the mesothelin-targeting ADC PF-08052666 PF-08052666 also called HBM9033 is from Habour Biomed in [----]. https://x.com/chuminhua432/status/1735645683368055070s=20 Habour Biomed (HBM) announced that Nona Biosciences a subsidiary wholly-owned by HBM and Seagenhave entered into a license agreement for the global clinical development and commercialization of HBM9033 MSLN ADCN developed by Nona Biosciences. https://t.co/c3cxAPgMHR https://t.co/J3yTOtVrj8 https://x.com/chuminhua432/status/1735645683368055070s=20 Habour Biomed (HBM) announced that Nona"
X Link 2026-01-21T15:51Z [----] followers, [----] engagements

"Shanghai Juncell Therapeutics presented its first registrational Phase I clinical data on TIL therapy GC101 for the treatment of advanced late-line NSCLC in ESMO-IO. GC101 is a modified natural TIL regimen using reduced-intensity preconditioning and no IL-2 in this refractory population. ORR was 41.7% (5/12 95% CI 15.2-72.3 %). Median DOR was not reached. Disease control rate was 66.7% (8/12 95% CI 34.9-90.1% [--] PR and [--] SD). Last month Juncell submitted HKSE IPO application. https://x.com/chuminhua432/status/1998734325878239341s=20"
X Link 2026-01-22T08:21Z [----] followers, [----] engagements

"$ABBV announced that risankizumab (Skyrizi) has received supplemental approval in China for a second indication: the treatment of adult patients with moderate to severe active ulcerative colitis (UC) who have had an inadequate unresponsive or intolerant attitude to conventional or biologic therapies. This new approval is based on positive results from the INSPIRE and COMMAND Phase III clinical trials. https://twitter.com/i/web/status/2014267721157054471 https://twitter.com/i/web/status/2014267721157054471"
X Link 2026-01-22T09:23Z [----] followers, [---] engagements

"Daiichi Sankyo announced that trastuzumab deruxtecan (Enhertu) has been approved in China for monotherapy in the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have previously received one trastuzumab-containing therapy. This is the sixth indication approved for Enhertu in China and the second indication related to HER2-positive gastric cancer. This new approval is based on the results of phase III DESTINY-Gastric04 clinical trial. https://twitter.com/i/web/status/2014269294532853981"
X Link 2026-01-22T09:29Z [----] followers, [---] engagements

"$AZN's Imfinzi (durvalumab) has been approved in China for a new indication: in combination with carboplatin and paclitaxel for first-line treatment of adult patients with dMMR primary advanced or recurrent endometrial cancer followed by maintenance therapy with durvalumab monotherapy. This is the seventh indication approved for durvalumab in China. This approval in China is based on the pre-specified subgroup analysis results according to MMR status from the DUO-E Phase [--] trial which has been published in JCO. https://twitter.com/i/web/status/2014624668746187197"
X Link 2026-01-23T09:02Z [----] followers, [---] engagements

"Dizal Pharmaceuticals' HKSE IPO application has been accepted. Established in [----] Dizal was a spin-off from $AZN. Dizal was AstraZeneca global oncology translational science center Innovative Medicine and Early Development Asia (iMED Asia). Dizal listed on the Shanghai Stock Exchange's STAR Market in December [----] and its latest market capitalization on the STAR Market is RMB [----] billion. https://www1.hkexnews.hk/app/sehk/2026/108125/documents/sehk26012301157.pdf https://www1.hkexnews.hk/app/sehk/2026/108125/documents/sehk26012301157.pdf"
X Link 2026-01-24T09:47Z [----] followers, [----] engagements

"After taking over Biotheus PD-L1/VEGF BsAb Pumitamig (BNT327) from $BNTX $BMY quickly initiated two global multicenter Phase 2/3 clinical trials in NSCLC. - Phase [--] ROSETTA Lung-202 (NCT07361510) 1L NSCLC patients with PD-L1 50% h2h Keytruda monotherapy. Primary endpoints: PFS and OS. - Phase [--] ROSETTA Lung-201 (NCT07361497) unresectable stage III NSCLC h2h Imfinzi. Primary endpoint PFS. Additionally $PFE submitted [--] IND applications in China for the PD-1/VEGF BsAb from 3SBio https://twitter.com/i/web/status/2015073973994947048 https://twitter.com/i/web/status/2015073973994947048"
X Link 2026-01-24T14:47Z [----] followers, [----] engagements

"After a prolonged downturn Chinese biotech financing rebounded in [----] with strong momentum in I&I and cell therapy alongside renewed interest in oligonucleotides though A-share IPOs remained conspicuously absent. Tracker on China Innovative Drug Licensing & Collaboration Deals In [----] Chinese private biopharmaceutical companies completed [---] financing deals totaling $5.5 billion up 32% in number and 25% in value year-over-year marking the highest total in the past five years. Analysis of monthly financing trends indicates that the majority of activity occurred in the second half of the year"
X Link 2026-01-26T04:45Z [----] followers, [----] engagements

"Suzhou-based Neowise Biotech a biotech focusing on TCR-T cell therapies for solid tumors announced the completion of a Series B #financing of over RMB [---] million. This round was co-led by Apricot Capital and a well-known industrial fund. Founded in [----] Neowise has developed a high-throughput high-sensitivity target antigen-natural TCR discovery platform. Pipeline: - NW-101C TCR-T cell therapy targeting PRAME in Phase [--] - NW-301V TCR-T cell therapy targeting KRAS G12V mutations. Preliminary results of FIH trial reported in ESMO2025"
X Link 2026-01-26T15:41Z [----] followers, [---] engagements

"Shanghai-based Best-Link Bioscience a biotech focused on the novel nanoconjugate drugs and precision nanodelivery technologies has completed a Series B financing round exceeding RMB [---] million. This round was jointly led by Hongcheng Investment and its affiliates (Sun-Novo Pharma and Hongyao Tech) and Yonjin Venture. Best-Link Bioscience has independently developed the nano-mediated polypeptide-drug conjugate (NMPDC) technology platform which can flexibly accommodate various payloads. Core assets: - BL0020: NMPDC targeting tumor microenvironment (TME) completed Phase [--] clinical trial data"
X Link 2026-01-29T07:49Z [----] followers, [---] engagements

"NeuShen Therapeutics an biotech focused on CNS field announced the completion of a tens of millions of US dollars Series A+ financing round. This round was led by Lilly Asia Ventures"
X Link 2026-01-29T08:32Z [----] followers, [----] engagements

"$NVS announced that Leqvio (inclisiran) has been approved by the China NMPA as an adjunct to diet therapy for the treatment of adults with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to lower low-density lipoprotein cholesterol (LDL-C). Leqvio was first approved in China in August [----] as an adjunct to diet therapy for the treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia https://twitter.com/i/web/status/2016815713902850383 https://twitter.com/i/web/status/2016815713902850383"
X Link 2026-01-29T10:08Z [----] followers, [--] engagements

"$NVS announced that Leqvio (inclisiran) has been approved by the China NMPA as an adjunct to diet therapy for the treatment of adults with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to lower low-density lipoprotein cholesterol (LDL-C). Leqvio was first approved in China in August [----] as an adjunct to diet therapy for the treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia including: in patients who have not achieved their LDL-C target despite treatment with the maximum tolerated dose of statins in"
X Link 2026-01-29T10:10Z [----] followers, [---] engagements

"The results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab injection (KN026) Anbenitamab (KN026) is an anti-HER2 bispecific antibody developed by Alphamab Oncology and CSPC' subsidiary JMT-Bio. The median PFS was [---] months in the Anbenitamab Group versus [---] months in the SOC Control Group (HR [----] p0.0001) representing a 75% reduction in the risk of disease progression or death. The median OS was [----] months and [----] months in the Anbenitamab and Control groups respectively (HR [----] p0.0001)"
X Link 2026-01-29T15:02Z [----] followers, [---] engagements

"$AZN enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals [--] next-generation therapies for obesity and type [--] diabetes. Once-monthly injectable weight management portfolio - [--] clinical-ready asset SYH2082 a long-acting GLP1R/GIPR agonist progressing into Phase I - [--] preclinical programmes with differing mechanisms Financial terms - upfront payment of $1.2 billion milestones of up to $3.5 billion across all programmes - AstraZeneca has the right to opt-in to co-commercialise these products. In June the companies already reached strategic"
X Link 2026-01-30T09:17Z [----] followers, [--] engagements

"$AZN enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals [--] next-generation therapies for obesity and type [--] diabetes. Once-monthly injectable weight management portfolio - [--] clinical-ready asset SYH2082 a long-acting GLP1R/GIPR agonist progressing into Phase I - [--] preclinical programmes with differing mechanisms Financial terms - upfront payment of $1.2 billion milestones of up to $3.5 billion across all programmes - up to US$13.8 billion in potential sales milestone payments plus up to double-digit royalties based on the annual net sales of the"
X Link 2026-01-30T09:30Z [----] followers, [--] engagements

"SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech $RHHBY - SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments totaling up to $1.5 billion plus tiered royalties - Genentech will be responsible for the subsequent clinical development and commercialization globally https://www.prnewswire.com/news-releases/sanegenebio-announces-rnai-global-licensing-collaboration-with-genentech-302676224.html"
X Link 2026-02-03T03:07Z [----] followers, [---] engagements

"Zhiben Pharma announced that its broad-spectrum androgen receptor (AR) molecular glue degrader ZB-002 jointly developed with Guizhou Medical University and the Shanghai Institute of Materia Medica Chinese Academy of Sciences has received IND approval in China. The approval allows for its monotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). ZB-002 is a molecular glue degrader (molecular weight [---] Da) targeting the AR-N terminal domain (AR-NTD). https://twitter.com/i/web/status/2018541540491297272 https://twitter.com/i/web/status/2018541540491297272"
X Link 2026-02-03T04:26Z [----] followers, [---] engagements

"Zonsen PepLib Biotech Enters Global R&D Collaboration and License Agreement with $LLY The two companies will leverage PepLib's proprietary peptide library and discovery technology platform to jointly advance the development of novel peptide candidates. Zonsen PepLib will be responsible for screening and identifying the optimal active peptide molecules while Eli Lilly will be responsible for subsequent IND-enabling studies clinical development and commercialization. Financial term didnot disclosed. Just last month Zonsen PepLib also entered into a licensing agreement with $NVS granting"
X Link 2026-02-03T07:31Z [----] followers, [----] engagements

"Beijing-based PrimeGenX Therapeutics's HKSE IPO application has been accepted. Founded in [----] PrimeGenX is a biotech focused on the field of immuneinflammation especially in locally delivered targeted therapies. Core Product PG-011 (Pumecitinib) JAK inhibitor in two dosage forms - Pumecitinib gel for atopic dermatitis - Pumecitinib nasal spray for allergic rhinitis https://www1.hkexnews.hk/app/sehk/2026/108119/documents/sehk26012101036.pdf https://www1.hkexnews.hk/app/sehk/2026/108119/documents/sehk26012101036.pdf https://www1.hkexnews.hk/app/sehk/2026/108119/documents/sehk26012101036.pdf"
X Link 2026-02-03T09:00Z [----] followers, [---] engagements

"OBI Pharma and Odeon Therapeutics had entered into an exclusive license agreement whereby OBI grants rights of ADC OBI-999 and OBI-833 a therapeutic cancer vaccine targeting the tumor antigen Globo H in China Hong Kong and Macau to https://www.prnewswire.com/news-releases/obi-pharma-enters-license-agreement-with-odeon-therapeutics-for-the-rights-of-obi-999-and-obi-833-in-china-hong-kong-and-macau-301485505.html https://www.prnewswire.com/news-releases/obi-pharma-enters-license-agreement-with-odeon-therapeutics-for-the-rights-of-obi-999-and-obi-833-in-china-hong-kong-and-macau-301485505.html"
X Link 2022-02-23T16:04Z [----] followers, [--] engagements

"#Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million The combined company will operate under the name ImageneBio Inc. and will begin trading on Nasdaq under the ticker symbol $IMA at market open on July [--] [----] https://inmagenebio.com/press_releases/inmagene-biopharmaceuticals-announces-completion-of-merger-with-ikena-oncology-and-concurrent-private-placement-of-75-million/"
X Link 2025-07-29T14:01Z [----] followers, [---] engagements

"$IMAB announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences. The Company also announced the pending acquisition of VIS-101 a novel bifunctional biologic targeting VEGF-A and ANG2. The pending acquisition will be made by a newly formed subsidiary Visara Inc. (Visara) a NewCo focused on developing ophthalmic therapeutics for serious eye disorders and is expected to be completed later this month. VIS-101 (also named lASKG712) is developed by ASK pharma the"
X Link 2025-10-17T16:56Z [----] followers, [----] engagements

"$TERN a pharma based on both US and China will not advance TERN-601 or invest in other metabolic assets after reported the topline 12-week results from its Phase [--] trial of TERN-601 a novel once-daily oral GLP-1RA https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2 https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2"
X Link 2025-10-22T14:50Z [----] followers, [----] engagements

"BeOne Medicines (formerly BeiGene) $ONC registered an international Ph1 clinical trial for BG-75098 monotherapy or in combination for the treatment of advanced solid tumors. This Ph1 trial plans to enroll [---] patients with advanced solid tumors. The combination therapy regimens include combination with the CDK4 inhibitor BGB-43395 and fulvestrant. According to information disclosed by BeOne at its [----] R&D Day BG-75098 is a CDK2 CDAC and also a potential first-in-class CDK2 degrader featuring superior potency selectivity and pharmacokinetic (PK) characteristics."
X Link 2025-11-11T15:44Z [----] followers, [----] engagements

"$MRK China announced that its first-in-class activin signalling inhibitor sotatercept (Winrevair) has been approved by NMPA for the treatment of adult patients with PAH of WHO functional class (FC) II-III in order to improve patients exercise capacity and WHO functional class. This approval is based on the data of the Phase [--] clinical trial STELLAR. https://twitter.com/i/web/status/2008095158256959666 https://twitter.com/i/web/status/2008095158256959666"
X Link 2026-01-05T08:36Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing